Drug Trial Radar · NCT06809179
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Jan 9, 2025
Primary completion
Jun 12, 2026
Study completion Aug 26, 2026
Sponsor
- Lead sponsor
- VistaGen Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PH94B-CL036 and choose to enter the distinct open-label extension phase of the study.
Conditions
- Social Anxiety Disorder
Interventions
Fasedienol Nasal Spray - Placebo Nasal SprayDrug
Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by one dose of Placebo Nasal Spray, separated by 10-minutes in between the two doses.
Fasedienol Nasal Spray - Fasedienol Nasal SprayDrug
Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by a second dose of Fasedienol Nasal Spray, separated by 10-minutes in between the two doses.
Placebo Nasal Spray - Placebo Nasal SprayDrug
Twenty minutes prior to the PSC, subjects will receive one dose of Placebo Nasal Spray followed by a second dose of Placebo Nasal Spray, separated by 10-minutes between the two doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjective Units of Distress Scale (SUDS)Time frame: 7 days (Visit 2 to Visit 3)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Vistagen Clinical Site
Sherman Oaks, California
Vistagen Clinical Site
Walnut Creek, California
Vistagen Clinical Site
Largo, Florida
Vistagen Clinical Site
Saint Charles, Missouri
Vistagen Clinical Site
Toms River, New Jersey
Vistagen Clinical Site
Cary, North Carolina
Vistagen Clinical Site
Cleveland, Ohio
Vistagen Clinical Site
Plymouth Meeting, Pennsylvania
Vistagen Clinical Site
Plano, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.